This study describes demographics, thrombotic and bleeding events, mortality, and
anticoagulant use among hospitalized patients with COVID-19 in the United States. Premier …

Background The coronavirus disease 2019 (COVID-19) causes extensive coagulopathy and
a potential benefit of anticoagulation therapy has been documented for prevention of …

Thrombotic complications from COVID-19 are now well known and contribute to significant
morbidity and mortality. Different variants confer varying risks of thrombotic complications …

Aim: Coronavirus disease 2019 (COVID-19) has been associated with increased mortality
and morbidity from thromboembolism, especially venous thromboembolism. There are more …

Purpose The clinical course of COVID-19 may be complicated by acute respiratory distress
syndrome (ARDS) and thromboembolic events, which are associated with high risk of …

Background Optimal thromboprophylaxis for hospitalized patients with coronavirus disease
2019 (Covid-19) is uncertain. Methods In an open-label, adaptive platform trial, we randomly …

Importance Venous thromboembolism (VTE) is a common complication of COVID-19. It is
not well understood how hospitals have managed VTE prevention and the effect of …

Background Randomised controlled trials (RCTs) have reported inconsistent effects from
intensified anticoagulation on clinical outcomes in Covid-19. We performed an aggregate …

Background Because of the high risk of thrombotic complications (TCs) during SARS-CoV-2
infection, several scientific societies have proposed to increase the dose of preventive …

Thrombotic complications occur at high rates in hospitalized patients with COVID‐19, yet the
impact of intensive antithrombotic therapy on mortality is uncertain. We examined in‐hospital …